Storia in 2 fonti

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Raccontata da

endpoints.news

biopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo21 h fa

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Sanofi's CEO prioritizes rebuilding Regeneron partnership while canceling amlitelimab and itepekimab programs ahead of Dupixent's patent cliff. The shift from internal R&D to M&A and partnerships reflects pharma consolidation under IP pressure.

originale

endpoints.news1 g fa

Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons

Regeneron & Sanofi discuss expanding partnership, potentially including Dupixent follow-ons. CEOs Schleifer & Garijo cite need to rebuild trust amid ongoing litigation.

Leggi questa versione →

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons

Timeline cronologica

Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs